1159 ET - Rani Therapeutics continues to take steps toward what could be a diverse pipeline of oral drugs in obesity, says Maxim Group's Michael Okunewitch in a research note. The analyst notes that two programs from the clinical stage bio-therapeutics company could be just the start of Rani's obesity strategy with potential to expand to other partnerships or even internal development programs as obesity drugs come off-patent. Okunewitch notes that given the roughly 70 million obese American adults, it's unlikely there will be a "one-drug-fits-all" approach. He adds that Rani's RT-114 is unlikely to reach the 20%+ weight reductions seen from the most potent drugs in the class but that not all users will require that magnitude of weight loss. Shares tick down 3% to $2.28. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
November 15, 2024 11:59 ET (16:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。